Abstract Sodium–glucose cotransporter-2 (SGLT2) inhibitors recently emerged as an
effective therapy for heart failure (HF) with reduced ejection fraction. Recent published …

We have read with great interest the article by Li et al.[1] who performed a meta-analysis to
explore the effects of sodium-glucose cotransporter 2 inhibitor (SGLT2i) on cardiovascular …

Aim To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiovascular outcomes in patients with heart failure with preserved ejection fraction …

Background To investigate the overall effect of sodium-glucose cotransporter-2 inhibitors
(SGLT-2i) on cardiovascular outcomes in a broad spectrum of heart failure (HF) patients …

It is highly improbable and incredibly fortuitous for a therapy to work across an entire
syndrome. As luck would have it, that syndrome is heart failure—perhaps the most common …

Heart failure with preserved ejection fraction (HFpEF) is a common and difficult-to-treat heart
disease. Approximately half of patients with heart failure suffer from this form, and mortality is …

It is well known that the prevalence of heart failure (HF) is high and continues to grow.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, although initially developed as a …

Abstract Funding Acknowledgements Type of funding sources: None. Aims We aimed to
carry out a meta-analysis on the effectiveness of sodium-glucose co transporter 2 (SGLT2) …

This Focus Issue on heart failure (HF) provides novel clinically relevant information on
sodium–glucose co-transporter-2 (SGLT2) inhibitors which, initially proposed for the …

SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
ARNI, angiotensin receptor–neprilysin inhibitor; CV, cardiovascular; GRMT, guideline …